Page 1 | Search Results | Blood Advances | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis

Chenyu Lin, Anand A. Patel, Dezheng Huo, Theodore Karrison, Koen van Besien, John Godwin, Dorie Sher, Howie Weiner, Margaret Green, James L. Wade, III, Rebecca Klisovic, Maria R. Baer, Richard A. Larson, Wendy Stock, Olatoyosi Odenike

Blood Adv (2024) 8 (22): 5735–5743.

https://doi.org/10.1182/bloodadvances.2024013215

Published: 2024

Includes: Supplemental data

Journal Articles

Association of social deprivation with survival in younger adult patients with AML: an Alliance study

Blood Adv (2023) 7 (15): 4019–4023.

https://doi.org/10.1182/bloodadvances.2022009325

Published: 2023

Includes: Supplemental data

Journal Articles

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT

Misha C. Tran, Yasmin Hasan, Amy Wang, Kamil Yenice, Julien Partouche, Wendy Stock, Richard A. Larson, Satyajit Kosuri, James L. LaBelle, Justin Kline, Peter A. Riedell, Andrew S. Artz, Ralph Weichselbaum, Michael R. Bishop, Bulent Aydogan, Hongtao Liu

Blood Adv (2023) 7 (3): 285–292.

https://doi.org/10.1182/bloodadvances.2022007530

Published: 2023

Includes: Supplemental data

Journal Articles

The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study

Ibrahim Aldoss, Jun Yin, Anna Wall, Krzysztof Mrózek, Michaela Liedtke, David F. Claxton, Matthew C. Foster, Frederick R. Appelbaum, Harry P. Erba, Mark R. Litzow, Martin S. Tallman, Richard M. Stone, Richard A. Larson, Anjali S. Advani, Wendy Stock, Selina M. Luger

Blood Adv (2023) 7 (2): 196–204.

https://doi.org/10.1182/bloodadvances.2022007791

Published: 2023

Includes: Supplemental data

Journal Articles

High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML

Blood Adv (2022) 6 (19): 5570–5581.

https://doi.org/10.1182/bloodadvances.2022007544

Published: 2022

Includes: Supplemental data

Journal Articles

Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia

Lori Muffly, Jun Yin, Sawyer Jacobson, Anna Wall, Elisa Quiroz, Anjali S. Advani, Selina M. Luger, Martin S. Tallman, Mark R. Litzow, Matthew C. Foster, Harry P. Erba, Frederick R. Appelbaum, Richard A. Larson, Theresa H.M. Keegan, Wendy Stock

Blood Adv (2022) 6 (14): 4085–4092.

https://doi.org/10.1182/bloodadvances.2022007197

Published: 2022

Includes: Supplemental data

Journal Articles

Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101

Ellen K. Ritchie, Heidi D. Klepin, Elizabeth Storrick, Brittny Major, Jennifer Le-Rademacher, Martha Wadleigh, Alison Walker, Richard A. Larson, Gail J. Roboz

Blood Adv (2022) 6 (12): 3812–3820.

https://doi.org/10.1182/bloodadvances.2021006872

Published: 2022

Includes: Supplemental data

Journal Articles

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia

Zachary D. Epstein-Peterson, Andriy Derkach, Susan Geyer, Krzysztof Mrózek, Jessica Kohlschmidt, Jae H. Park, Sridevi Rajeeve, Eytan M. Stein, Yanming Zhang, Harry Iland, Lynda J. Campbell, Richard A. Larson, Xavier Poiré, Bayard L. Powell, Wendy Stock, Richard M. Stone, Martin S. Tallman

Blood Adv (2022) 6 (11): 3433–3439.

https://doi.org/10.1182/bloodadvances.2021006682

Published: 2022

Journal Articles

Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL

Matthew J. Wieduwilt, Jun Yin, Meir Wetzler, Geoffrey L. Uy, Bayard L. Powell, Jonathan E. Kolitz, Michaela Liedtke, Wendy Stock, Jan H. Beumer, Ryan J. Mattison, Elizabeth Storrick, Susan M. Christner, Lionel D. Lewis, Steven Devine, Richard M. Stone, Richard A. Larson

Blood Adv (2021) 5 (22): 4691–4700.

https://doi.org/10.1182/bloodadvances.2021004813

Published: 2021

Includes: Supplemental data

Journal Articles

Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy

Anand Ashwin Patel, Alexandra E. Rojek, Michael W. Drazer, Howard Weiner, Lucy A. Godley, Michelle M. Le Beau, Richard A. Larson

Blood Adv (2021) 5 (20): 4140–4148.

https://doi.org/10.1182/bloodadvances.2021004964

Published: 2021

Includes: Supplemental data

Journal Articles

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Blood Adv (2021) 5 (13): 2775–2787.

https://doi.org/10.1182/bloodadvances.2021004233

Published: 2021

Includes: Supplemental data

Journal Articles

Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia

Blood Adv (2021) 5 (2): 504–512.

https://doi.org/10.1182/bloodadvances.2020002439

Published: 2021

Includes: Supplemental data

Journal Articles

Midostaurin in patients with acute myeloid leukemia and FLT3 -TKD mutations: a subanalysis from the RATIFY trial

Blood Adv (2020) 4 (19): 4945–4954.

https://doi.org/10.1182/bloodadvances.2020002904

Published: 2020

Includes: Supplemental data

Journal Articles

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

Guido Marcucci, Susan Geyer, Kristina Laumann, Weiqiang Zhao, Donna Bucci, Geoffrey L. Uy, William Blum, Ann-Kathrin Eisfeld, Timothy S. Pardee, Eunice S. Wang, Wendy Stock, Jonathan E. Kolitz, Jessica Kohlschmidt, Krzysztof Mrózek, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson

Blood Adv (2020) 4 (4): 696–705.

https://doi.org/10.1182/bloodadvances.2019000492

Published: 2020

Journal Articles

A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia

Kirk E. Cahill, Yasmin H. Karimi, Theodore G. Karrison, Nitin Jain, Margaret Green, Howard Weiner, Noreen Fulton, Sabah Kadri, Lucy A. Godley, Andrew S. Artz, Hongtao Liu, Michael J. Thirman, Michelle M. Le Beau, Megan E. McNerney, Jeremy Segal, Richard A. Larson, Wendy Stock, Olatoyosi Odenike

Blood Adv (2020) 4 (4): 599–606.

https://doi.org/10.1182/bloodadvances.2019000795

Published: 2020

Includes: Supplemental data

Journal Articles

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes

Blood Adv (2019) 3 (24): 4228–4237.

https://doi.org/10.1182/bloodadvances.2019000925

Published: 2019

Includes: Supplemental data

Journal Articles

Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults

Blood Adv (2019) 3 (22): 3488–3498.

https://doi.org/10.1182/bloodadvances.2019000790

Published: 2019

Includes: Supplemental data

Journal Articles

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)

Jun Yin, Betsy LaPlant, Geoffrey L. Uy, Guido Marcucci, William Blum, Richard A. Larson, Richard M. Stone, Sumithra J. Mandrekar

Blood Adv (2019) 3 (11): 1714–1721.

https://doi.org/10.1182/bloodadvances.2018026112

Published: 2019

Includes: Supplemental data

Journal Articles

Imatinib is still recommended for frontline therapy for CML

Andrew Hantel, Richard A. Larson

Blood Adv (2018) 2 (24): 3648–3652.

https://doi.org/10.1182/bloodadvances.2018018614

Published: 2018

Journal Articles

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

Blood Adv (2018) 2 (24): 3608–3617.

https://doi.org/10.1182/bloodadvances.2018023689

Published: 2018

Includes: Supplemental data

NARROW

A multicenter phase 2 clinical trial of low-dose subcutaneous decitabine in myelofibrosis

Association of social deprivation with survival in younger adult patients with AML: an Alliance study

A phase 1 trial utilizing TMI with fludarabine-melphalan in patients with hematologic malignancies undergoing second allo-SCT

The impact of early PEG-asparaginase discontinuation in young adults with ALL: a post hoc analysis of the CALGB 10403 study

High early death rates, treatment resistance, and short survival of Black adolescents and young adults with AML

Disparities in trial enrollment and outcomes of Hispanic adolescent and young adult acute lymphoblastic leukemia

Geriatric assessment for older adults receiving less-intensive therapy for acute myeloid leukemia: report of CALGB 361101

Effect of additional cytogenetic abnormalities on survival in arsenic trioxide-treated acute promyelocytic leukemia

Dasatinib and dexamethasone followed by hematopoietic cell transplantation for adults with Ph-positive ALL

Therapy-related myeloid neoplasms in 109 patients after radiation monotherapy

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia

Midostaurin in patients with acute myeloid leukemia and FLT3 -TKD mutations: a subanalysis from the RATIFY trial

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

A phase 1 study of azacitidine with high-dose cytarabine and mitoxantrone in high-risk acute myeloid leukemia

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes

Results from a multidisciplinary clinic guided by geriatric assessment before stem cell transplantation in older adults

Evaluation of event-free survival as a robust end point in untreated acute myeloid leukemia (Alliance A151614)

Imatinib is still recommended for frontline therapy for CML

Randomized trial of 10 days of decitabine ± bortezomib in untreated older patients with AML: CALGB 11002 (Alliance)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only